Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for Vanda Pharmaceuticals Inc
12.51
-0.22 (-1.73%)
Real-time:   1:16PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.38 - 12.72
52 week 8.34 - 19.25
Open 12.70
Vol / Avg. 278,367.00/505,951.00
Mkt cap 505.57M
P/E     -
Div/yield     -
EPS -1.69
Shares 39.65M
Beta 1.93
Inst. own 105%
Feb 11, 2015
Q4 2014 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 3, 2014
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 18, 2014
Vanda Pharmaceuticals Inc at Stifel Healthcare Conference - Webcast
Oct 27, 2014
Q3 2014 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Oct 27, 2014
Q3 2014 Vanda Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9.65% -59.79%
Operating margin -9.80% -60.21%
EBITD margin - -54.53%
Return on average assets -6.92% -14.53%
Return on average equity -587.24% -74.98%
Employees 53 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 72
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters
H. Thomas Watkins Independent Director
Age: 61
Bio & Compensation  - Reuters